ARNA
Income statement / Annual
Last year (2021), Arena Pharmaceuticals, Inc.'s total revenue was $54,000.00,
a decrease of 83.07% from the previous year.
In 2021, Arena Pharmaceuticals, Inc.'s net income was -$620.59 M.
See Arena Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$54,000.00 |
$319,000.00 |
$806.43 M |
$17.97 M |
$21.34 M |
$123.98 M |
$38.33 M |
$36.97 M |
$81.39 M |
$27.59 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$15.34 M
|
$13.18 M
|
$7.76 M
|
$6.18 M
|
$3.67 M
|
| Gross Profit |
$54,000.00
|
$319,000.00
|
$806.43 M
|
$17.97 M
|
$21.34 M
|
$108.63 M
|
$25.15 M
|
$29.21 M
|
$75.21 M
|
$23.92 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
0.88
|
0.66
|
0.79
|
0.92
|
0.87
|
| Research and Development Expenses |
$419.51 M
|
$323.74 M
|
$231.50 M
|
$115.03 M
|
$70.99 M
|
$66.43 M
|
$88.41 M
|
$100.35 M
|
$66.47 M
|
$54.11 M
|
| General & Administrative Expenses |
$126.20 M
|
$103.20 M
|
$77.60 M
|
$47.70 M
|
$30.30 M
|
$31.20 M
|
$36.00 M
|
$34.10 M
|
$31.70 M
|
$26.20 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$126.20 M
|
$103.20 M
|
$77.60 M
|
$47.70 M
|
$30.30 M
|
$31.20 M
|
$36.00 M
|
$34.10 M
|
$31.70 M
|
$26.20 M
|
| Other Expenses |
$8.64 M
|
$0.00
|
$14.57 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$691,000.00
|
| Operating Expenses |
$554.35 M
|
$426.94 M
|
$323.67 M
|
$162.73 M
|
$101.29 M
|
$97.63 M
|
$124.41 M
|
$134.45 M
|
$98.17 M
|
$81.00 M
|
| Cost And Expenses |
$554.35 M
|
$426.94 M
|
$323.67 M
|
$162.73 M
|
$101.29 M
|
$112.97 M
|
$137.59 M
|
$142.21 M
|
$104.35 M
|
$84.67 M
|
| Interest Income |
$1.43 M
|
$11.05 M
|
$26.87 M
|
$8.77 M
|
$492,000.00
|
$290,000.00
|
$158,000.00
|
$83,000.00
|
$89,000.00
|
$119,000.00
|
| Interest Expense |
$4.16 M
|
$4.52 M
|
$4.79 M
|
$5.70 M
|
$6.12 M
|
$6.51 M
|
$6.83 M
|
$6.92 M
|
$7.09 M
|
$9.12 M
|
| Depreciation & Amortization |
$3.87 M
|
$3.86 M
|
$3.23 M
|
$3.76 M
|
$4.28 M
|
$9.36 M
|
$10.04 M
|
$9.16 M
|
$8.20 M
|
$9.75 M
|
| EBITDA |
-$608.40 M |
-$396.35 M |
$515.91 M |
-$130.21 M |
-$81.01 M |
-$6.65 M |
-$91.11 M |
-$44.43 M |
-$4.14 M |
-$66.61 M |
| EBITDA Ratio |
-11266.7
|
-1242.49
|
0.64
|
-7.25
|
-3.8
|
-0.05
|
-2.38
|
-1.2
|
-0.05
|
-2.41
|
| Operating Income Ratio |
-11338.41
|
-1337.43
|
0.6
|
-8.06
|
-4.31
|
-0.14
|
-2.69
|
-2.85
|
-0.28
|
-2.07
|
| Total Other Income/Expenses Net |
-$4.16 M
|
$21.91 M
|
$25.14 M
|
$5.95 M
|
-$3.85 M
|
-$5.71 M
|
-$4.82 M
|
$44.80 M
|
$3.48 M
|
-$28.34 M
|
| Income Before Tax |
-$616.43 M
|
-$404.73 M
|
$507.89 M
|
-$138.83 M
|
-$95.81 M
|
-$22.85 M
|
-$108.01 M
|
-$60.47 M
|
-$19.45 M
|
-$85.45 M
|
| Income Before Tax Ratio |
-11415.43
|
-1268.76
|
0.63
|
-7.73
|
-4.49
|
-0.18
|
-2.82
|
-1.64
|
-0.24
|
-3.1
|
| Income Tax Expense |
$4.16 M
|
$26.43 M
|
$110.33 M
|
-$110.27 M
|
$2.27 M
|
$805,000.00
|
$2.01 M
|
$51.72 M
|
$10.57 M
|
-$19.22 M
|
| Net Income |
-$620.59 M
|
-$404.73 M
|
$397.56 M
|
-$29.40 M
|
-$91.41 M
|
-$22.52 M
|
-$107.98 M
|
-$60.51 M
|
-$19.44 M
|
-$85.48 M
|
| Net Income Ratio |
-11492.44
|
-1268.76
|
0.49
|
-1.64
|
-4.28
|
-0.18
|
-2.82
|
-1.64
|
-0.24
|
-3.1
|
| EPS |
-11.33 |
-7.39 |
7.69 |
-0.62 |
-2.77 |
-0.93 |
-4.49 |
-2.75 |
-0.89 |
-4.35 |
| EPS Diluted |
-11.33 |
-7.39 |
7.69 |
-0.62 |
-2.77 |
-0.93 |
-4.49 |
-2.75 |
-0.89 |
-4.35 |
| Weighted Average Shares Out |
$54.77 M
|
$54.77 M
|
$51.70 M
|
$47.04 M
|
$32.99 M
|
$24.31 M
|
$24.07 M
|
$21.97 M
|
$21.81 M
|
$19.65 M
|
| Weighted Average Shares Out Diluted |
$54.77 M
|
$54.77 M
|
$51.70 M
|
$47.04 M
|
$32.99 M
|
$24.31 M
|
$24.07 M
|
$21.97 M
|
$21.81 M
|
$19.65 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
